Aparna R. Parikh, MD

home / authors / aparna-parikh-md

Articles

Dr Parikh on Available Treatment Options for HER2+ CRC

November 7th 2024

Aparna Parikh, MD, discusses currently available treatment options for patients with HER2-positive colorectal cancer.

Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies

Dr Parikh on Currently Available Targeted Treatment Approaches for Mutated CRC

Aparna R. Parikh, MD

October 29th 2024

Aparna Parikh, MD, discusses currently available targeted therapy options for patients with colorectal cancer.

Key Takeaways and Closing Thoughts on ADCs

VK Gadi, MD, PhD;Susana M. Campos, MD, MPH;Matthew Galsky, MD;Edward B. Garon, MD, MS;Aparna R. Parikh, MD

August 29th 2024

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

Emerging ADCs in Development

VK Gadi, MD, PhD;Susana M. Campos, MD, MPH;Matthew Galsky, MD;Edward B. Garon, MD, MS;Aparna R. Parikh, MD

August 22nd 2024

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

ADC Sequencing

VK Gadi, MD, PhD;Susana M. Campos, MD, MPH;Matthew Galsky, MD;Edward B. Garon, MD, MS;Aparna R. Parikh, MD

August 22nd 2024

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.

Dr Parikh on the Rationale for Adding ERAS-007 to the BEACON Regimen in BRAF V600E–Mutant mCRC

Aparna R. Parikh, MD

August 21st 2024

Aparna Parikh, MD, discusses the rationale for adding ERAS-007 to the BEACON regimen in BRAF V600E–mutated metastatic colorectal cancer.

Management of Emetogenicity of Antibody-Drug Conjugates

VK Gadi, MD, PhD;Susana M. Campos, MD, MPH;Matthew Galsky, MD;Edward B. Garon, MD, MS;Aparna R. Parikh, MD

August 15th 2024

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

Managing Hematologic AEs Associated with ADC Treatments

VK Gadi, MD, PhD;Susana M. Campos, MD, MPH;Matthew Galsky, MD;Edward B. Garon, MD, MS;Aparna R. Parikh, MD

August 15th 2024

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

Managing Toxicities in Short- and Long-Term Treatment with ADCs

Vijayakrishna Gadi, MD, University of Illinois College of Medicine;Susana Campos, MD, MPH;Matthew D. Galsky, MD;Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA;Aparna R. Parikh, MD

Published: August 8th 2024 | Updated: July 23rd 2024

Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.

Managing ILD and Pneumonitis Risk From ADCs

Vijayakrishna Gadi, MD, University of Illinois College of Medicine;Susana Campos, MD, MPH;Matthew D. Galsky, MD;Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA;Aparna R. Parikh, MD

Published: August 8th 2024 | Updated: July 23rd 2024

Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.

The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines

Vijayakrishna Gadi, MD, University of Illinois College of Medicine;Susana Campos, MD, MPH;Matthew D. Galsky, MD;Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA;Aparna R. Parikh, MD

Published: August 1st 2024 | Updated: July 23rd 2024

Vijayakrishna Gadi, MD, PhD, discusses the role of antibody-drug conjugates in a curative setting.

Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types

Vijayakrishna Gadi, MD, University of Illinois College of Medicine;Susana Campos, MD, MPH;Matthew D. Galsky, MD;Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA;Aparna R. Parikh, MD

Published: August 1st 2024 | Updated: July 23rd 2024

A panel of experts discuss the challenges of testing for HER2-low access solid tumor types.

ADCs Targeting HER2+ GU Cancers

Vijayakrishna Gadi, MD, University of Illinois College of Medicine;Susana Campos, MD, MPH;Matthew D. Galsky, MD;Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA;Aparna R. Parikh, MD

Published: July 23rd 2024 | Updated: July 23rd 2024

A panel of experts discuss if there is a role for HER2-directed ADCs antibody-drug conjugates in GU genitourinary cancers

Impact of ADCs on Brain Metastases

Vijayakrishna Gadi, MD, University of Illinois College of Medicine;Susana Campos, MD, MPH;Matthew D. Galsky, MD;Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA;Aparna R. Parikh, MD

Published: July 23rd 2024 | Updated: July 23rd 2024

A panel of experts discuss where HER2-directed ADCs antibody-drug conjugates fit into the overall treatment paradigm.

ADCs Targeting HER2+ Lung Cancer

Vijayakrishna Gadi, MD, University of Illinois College of Medicine;Susana Campos, MD, MPH;Matthew D. Galsky, MD;Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA;Aparna R. Parikh, MD

Published: July 12th 2024 | Updated: July 12th 2024

Dr Garon shares insights on the role of ADCs for the treatment of HER2+ lung cancer.

Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

Vijayakrishna Gadi, MD, University of Illinois College of Medicine;Susana Campos, MD, MPH;Matthew D. Galsky, MD;Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA;Aparna R. Parikh, MD

July 12th 2024

Dr Gadi leads a discussion on recent data on the treatment of HER2-low tumors, including ASCO updates on the DESTINY-Breast06 trial.

ADCs Targeting GI Cancers

Vijayakrishna Gadi, MD, University of Illinois College of Medicine;Susana Campos, MD, MPH;Matthew D. Galsky, MD;Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA;Aparna R. Parikh, MD

Published: July 12th 2024 | Updated: July 12th 2024

Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.

ADCs Targeting HER2+ Gynecologic Cancers

Vijayakrishna Gadi, MD, University of Illinois College of Medicine;Susana Campos, MD, MPH;Matthew D. Galsky, MD;Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA;Aparna R. Parikh, MD

July 12th 2024

Dr Campos discusses the potential for T-DXd in other gynecologic cancers and offers an overview of results from the DESTINY-PanTumor02 trial.

Dr Parikh on Outcomes from the HERKULES-3 Trial in BRAF V600E–Mutant mCRC

Aparna R. Parikh, MD

June 26th 2024

Aparna Parikh, MD, discusses outcomes from the HERKULES-3 trial in BRAF V600E–mutated metastatic colorectal cancer.

ADCs Targeting HER2+ Breast Cancer

Vijayakrishna Gadi, MD, University of Illinois College of Medicine;Susana Campos, MD, MPH;Matthew D. Galsky, MD;Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA;Aparna R. Parikh, MD

June 25th 2024

Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.

Assessing HER2 Status Across Tumor Types

Vijayakrishna Gadi, MD, University of Illinois College of Medicine;Susana Campos, MD, MPH;Matthew D. Galsky, MD;Edward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA;Aparna R. Parikh, MD

June 25th 2024

Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.

A panel of 6 experts on colorectal cancer

Anticipating Key Studies and Pipeline Treatments in mCRC Landscape

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

April 11th 2024

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

Unmet Needs Surrounding mCRC Treatment

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

April 11th 2024

Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.

Richard Kim, MD, an expert on colorectal cancer

Data Surrounding Treatment for MSI-high Patients from ASCO 2024

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

April 4th 2024

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

Real-World Data Surrounding Sequencing Strategies for Refractory mCRC

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD;Scott Paulson, MD

April 4th 2024

Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.

Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

March 28th 2024

Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.

Considerations for Platinum-based Therapy

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

March 28th 2024

Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.

Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

March 21st 2024

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies

Aparna R. Parikh, MD;Marwan G. Fakih, MD;Richard Kim, MD;Scott Paulson, MD;Mark A. Lewis, MD;Joleen M. Hubbard, MD

March 21st 2024

Side effect profiles driven by fruquintinib use are discussed.